Researchers used NGS to profile the tumors of metastatic colorectal carcinoma patients enrolled in the CAPRI-GOIM clinical trial.
The company is embarking on a study of up to 2,000 patients to compare its tissue-based targeted sequencing assay with its cell-free DNA test.
Researchers have created panels for ovarian hyperstimulation syndrome and to detect mutations in BCR-ABL1 gene fusions.
Diagnostic sequencing will be done on the Illumina HiSeq X Ten, the HiSeq 2500, and the NextSeq 500 in HudsonAlpha's CLIA-certified Genomics Services Laboratory.
The privately-held German firm also plans to offer genetic tumor profiling and noninvasive prenatal testing.
In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.
Cancer clinical trial patients settle with Anil Potti and Duke University.
A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.
Two Johns Hopkins researchers discuss the need for evidence-based data analysis.